Psyence Biomedical Ltd. Share Price

Equities

PBM

CA74449F1009

Pharmaceuticals

End-of-day quote Nasdaq 03:30:00 27/06/2024 am IST 5-day change 1st Jan Change
0.329 USD -7.53% Intraday chart for Psyence Biomedical Ltd. -15.64% -96.44%
Sales 2022 - Sales 2023 - Capitalization 13Cr 1.1TCr
Net income 2022 -20L -17Cr Net income 2023 -40L -33Cr EV / Sales 2022 -
Net cash position 2022 21.91L 18Cr Net cash position 2023 18.06L 15Cr EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
-
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 23.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.53%
1 week-15.64%
Current month-56.13%
1 month-55.25%
3 months-71.14%
6 months-96.44%
Current year-96.44%
More quotes
1 week
0.27
Extreme 0.2666
0.41
1 month
0.27
Extreme 0.2666
0.79
Current year
0.27
Extreme 0.2666
12.60
1 year
0.27
Extreme 0.2666
14.55
3 years
0.27
Extreme 0.2666
14.55
5 years
0.27
Extreme 0.2666
14.55
10 years
0.27
Extreme 0.2666
14.55
More quotes
Date Price Change Volume
28/24/28 0.3 -8.81% 361,707
27/24/27 0.329 -7.53% 550,205
26/24/26 0.3558 -3.26% 300,588
25/24/25 0.3678 -1.00% 287,543
24/24/24 0.3715 -4.74% 990,289

End-of-day quote Nasdaq, June 27, 2024

More quotes
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
More about the company